Showing 1021-1030 of 20877 results for "".
- Teva Advances Anti-IL-15 Antibody Into Phase 2b for Vitiligohttps://reachmd.com/news/teva-advances-anti-il-15-antibody-into-phase-2b-for-vitiligo/2487696/Teva Pharmaceutical Industries Ltd. has announced plans to advance its investigational anti-interleukin-15 (IL-15) monoclonal antibody (TEV-'408) into a Phase 2b clinical trial for non-segmental vitiligo (NSV) in the fourth quarter of 2026 following encouraging in
- Global Survey Highlights Widespread Skin Quality Concerns and Emotional Impacthttps://reachmd.com/news/global-survey-highlights-widespread-skin-quality-concerns-and-emotional-impact/2487693/A new global survey commissioned by Galderma found that skin quality concerns are nearly universal, with 9 in 10 respondents reporting at least 1 concern during the previous month and most experiencing an average of 2 concerns.1 The survey included more than 11,000 participants
- Otsuka Reports Two-Year VISIONARY EGFR Results in IgA Nephropathyhttps://reachmd.com/news/otsuka-reports-two-year-visionary-egfr-results-in-iga-nephropathy/2487671/Key Takeaways The topline readout centered on eGFR and was described as showing statistically significant kidney-function stabilization versus placebo over two years, with evidence of improvement. VOYXACT was characterized as well tolerated, with a fav
- Oral Infigratinib in Pediatric Achondroplasia: Phase 3 Trialhttps://reachmd.com/news/oral-infigratinib-phase-3-pediatric-achondroplasia/2487658/Key Takeaways A greater week-52 change from baseline in annualized height velocity was observed with infigratinib than with placebo. Change in height z score also favored infigratinib, while change in upper-to-lower body segment ratio showed a small be
- Meta-analysis: Topical Ivermectin, Encapsulated BPO Show Strongest Efficacy in Rosaceahttps://reachmd.com/news/topical-ivermectin-encapsulated-benzoyl-peroxide-show-strongest-efficacy-in-rosacea-network-meta-analysis/2487668/A systematic review and network meta-analysis of randomized clinical trials suggests that topical ivermectin and encapsulated benzoyl peroxide (E-BPO) provide greater efficacy than metronidazole for adults with moderate to severe rosacea.
- Mediterranean Diet, Fat Intake, and Lung Cancer Outcomeshttps://reachmd.com/news/mediterranean-diet-fat-lung-cancer/2487634/Key Takeaways Greater Mediterranean diet adherence was associated with lower lung cancer incidence and lower lung cancer-specific mortality after adjustment. Higher polyunsaturated fat intake was associated with lower incidence and mortality, whereas h
- Artificial Intelligence in Histopathology and Cytopathologyhttps://reachmd.com/news/artificial-intelligence-in-histopathology-and-cytopathology/2487615/Key Takeaways High diagnostic accuracy was described across reviewed tasks, with controlled evaluations often reporting performance comparable to expert pathologists. The six included reviews covered use cases such as prostate carcinoma, lymphoma, meta
- Intensive LDL Cholesterol Targeting in Atherosclerotic Cardiovascular Diseasehttps://reachmd.com/news/intensive-ldl-cholesterol-targeting-in-atherosclerotic-cardiovascular-disease/2487613/Key Takeaways The lower LDL target was associated with fewer primary composite cardiovascular events during 3 years of follow-up. Median LDL cholesterol during the trial was 56 mg/dL with intensive targeting and 66 mg/dL with conventional targeting.
- Remote Monitoring After Sepsis Did Not Improve Home Dayshttps://reachmd.com/news/remote-monitoring-after-sepsis-did-not-improve-home-days/2487600/Key Takeaways Remote therapeutic monitoring did not improve postdischarge home days compared with usual care. Readmissions, mortality, and other secondary outcomes were not meaningfully different across groups overall. Less favorable subgroup
- Adjunctive D-Cycloserine in Fibromyalgia iTBS Trialhttps://reachmd.com/news/adjunctive-d-cycloserine-in-fibromyalgia-itbs-trial/2487596/Key Takeaways Adjunctive D-cycloserine was not associated with better FIQR change than placebo at treatment end, and enrollment stopped for futility. Both groups showed marked overall FIQR improvement, while depressive symptoms and clinician-rated CGI-